EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Intravenous methylprednisolone for nephrotic syndrome with minimal change lesions: a randomized controlled trial

Jinxia Chen, Ruting Li, Hua Guo, Tianyu Zhu, Yongzhi Xu, Cuiwei Yao, Huafeng Liu

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfae208 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Jinxia Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, National Clinical Key Specialty Construction Program (2023); Institute of Nephrology; Guangdong Provincial Key Laboratory o…. Hauptthemen laut MEDLINE: Methylprednisolone, Nephrosis, Lipoid, Glucocorticoids, Nephrotic Syndrome. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zhanjiang Science and Technology Project, Competitive Project of Financial Special Funds for Science and Technology of Zhanjiang City, National Clinical Key Specialty Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with minimal change nephrotic syndrome (MCNS) usually experience severe oedema, which can affect the absorption of oral corticosteroid during the first 2 weeks. We conducted a randomized controlled trial (RCT) to compare the efficacy of intravenous (IV) isovalent methylprednisolone induction followed by oral prednisone therapy with conventional oral prednisone therapy in highly oedematous MCNS patients, aiming to provide a better therapy for MCNS patients.

Methods

A single-centre, open-label, parallel-arm RCT was performed in the Nephrology Department of the Affiliated Hospital of Guangdong Medical University. Patients who met the inclusion criteria were enrolled in our study from May 2015 to October 2020 and were randomized to receive conventional oral steroid or 2 weeks of IV methylprednisolone followed by oral prednisone.

Results

A total of 117 patients were enrolled and randomly assigned to either the sequential group (n = 57) or the oral group (n = 60). The total remission rate in the sequential group was higher than in the oral group after treatment for 2 weeks and 4 weeks (P = .032, P = .027). The complete remission (CR) rate was higher in the sequential group than in the oral group (63.3% versus 41.5%; P = .031) after treatment for 2 weeks. The time to achieve CR was shorter in the sequential group than in the oral group, with a statistically significant difference {14.0 days [95% confidence interval (CI) 13.5–14.5] versus 16.0 days [95% CI 12.7–19.3], P = .024}. There were no significant differences in relapse rate (24.5% versus 28.3%; P = .823) and time to relapse (155 ± 103 days versus 150.7 ± 103.7 days; P = .916) between two groups.

Conclusion

This study suggested that highly oedematous MCNS patients who received IV isovalent methylprednisolone induction therapy followed by oral prednisone achieved earlier remission than the conventional oral prednisone regimen without differences in relapse rates or adverse effects. Short-term IV methylprednisolone followed by oral prednisone may be a better choice for MCNS patients with severe oedema.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethylprednisoloneNephrosis, LipoidGlucocorticoidsNephrotic SyndromeHumansMaleFemaleAdultMiddle AgedAdministration, IntravenousFollow-Up StudiesPrognosisAdministration, OralRemission InductionPrednisone

Stichwörter der Autor:innen

intravenousmethylprednisoloneminimal change nephrotic syndromeoedemaprednisone

Substanzen

MethylprednisoloneGlucocorticoidsPrednisone

Autor:innen und Institutionen

  • Department of Nephrology, National Clinical Key Specialty Construction Program (2023); Institute of Nephrology; Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases; Key Laborator…
  • Department of Nephrology, Boai hospital of Zhongshan, Zhongshan Women and Children's hospital, Affiliated Hospital of Southern Medical University, Zhongshan, China.
  • Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University, Nantong, People's Republic of China.
  • Nephrology Department, Dongguan People's Hospital Affiliated to Southern Medical University, Dongguan, People's Republic of China.

Förderung

  • Zhanjiang Science and Technology Project
  • Competitive Project of Financial Special Funds for Science and Technology of Zhanjiang City
  • National Clinical Key Specialty Construction Project
  • Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases

Zitieren

APA

Chen, J., Li, R., Guo, H., Zhu, T., Xu, Y., Yao, C., & Liu, H. (2025). Intravenous methylprednisolone for nephrotic syndrome with minimal change lesions: a randomized controlled trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae208

Vancouver

Chen J, Li R, Guo H, Zhu T, Xu Y, Yao C, et al. Intravenous methylprednisolone for nephrotic syndrome with minimal change lesions: a randomized controlled trial. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfae208

BibTeX
@article{Chen2025,
  author = {Chen, Jinxia and Li, Ruting and Guo, Hua and Zhu, Tianyu and Xu, Yongzhi and Yao, Cuiwei and Liu, Huafeng},
  title = {Intravenous methylprednisolone for nephrotic syndrome with minimal change lesions: a randomized controlled trial},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfae208}
}
Kostenlos starten →